title: Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure.
authors.forename: R
authors.initials: R
authors.lastname: Inauen
authors.forename: R
authors.initials: R
authors.lastname: Cathomas
authors.forename: T
authors.initials: T
authors.lastname: Boehm
authors.forename: D
authors.initials: D
authors.lastname: Koeberle
authors.forename: B C
authors.initials: BC
authors.lastname: Pestalozzi
authors.forename: S
authors.initials: S
authors.lastname: Gillessen
authors.forename: R
authors.initials: R
authors.lastname: von Moos
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab